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Hereditary haemophagocytic lymphohistiocytosis (HLH) is a fatal inflammatory
disease and treatments currently may lead to serious side effects. There is a
pressing need for effective, less toxic treatments for this disease. Previous reports
have suggested that interferon g (IFNg) has a role in the pathogenesis of HLH. Here,
we report that blocking IFNg had a therapeutic effect in two different murine
models of human hereditary HLH (perforin-deficient and Rab27a-deficient mice,
both infected with lymphocytic choriomeningitis virus). Therapeutic adminis-
tration of an anti-IFNg antibody induced recovery from haemophagocytosis in
both genetic models, as evidenced by increased survival in perforin-deficient mice
and correction of blood cytopenia, moderation of body temperature changes,
decreased cytokinaemia, restoration of splenic architecture and reduced haemo-
phagocytosis in the liver of bothmurinemodels. Involvement of the central nervous
system in Rab27a-deficientmicewas prevented by anti-IFNg therapy. Hepatic T-cell
infiltrates and virus persisted, with no detectable harm during the time course of
these studies.These data strongly suggest that neutralization of IFNg could be used
in humans to safely alleviate the clinical manifestations of haemophagocytosis.
INTRODUCTION
Hereditary haemophagocytic lymphohistiocytosis (HLH) is a
fatal inflammatory disease characterized by fever, an enlarged
spleen, cytopenia, elevated blood ferritin, coagulopathy, blood
lipid changes and may also lead to neurological symptoms
(Henter et al, 2007). It is the consequence of hypercytokinaemia
and organ infiltration by CD8-positive T-cells and macrophages
and is probably caused by genetic defects that impair cell-
mediated cytotoxicity, e.g.mutations in the genes which encode
perforin, Munc13-4, syntaxin-11, the lysosomal trafficking
regulator (LYST) and Rab27a (Barbosa et al, 1996; Feldmann
et al, 2003; Menasche et al, 2000; Nagle et al, 1996; Perou et al,
1996; Stepp et al, 1999; zur Stadt et al, 2005). However, the
same clinical syndrome can be observed in patients who do
not have any of these known, inherited defects; these
acquired forms of HLH can occur in patients suffering from
severe infections (e.g. HIV and H5N1-influenza), malignancies
and autoimmune, autoinflammatory or rheumatic diseases
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(Emmenegger et al, 2005; Hsieh & Chang, 2006) and are also
potentially fatal.
The only definite curative therapy for inherited forms of
HLH is haematopoietic stem cell transplantation (Fischer et al,
1986). Nevertheless, about 20–25% of the patients die
before transplantation due to failure of therapy or the serious
side effects of the immunosuppressive (such as antithymoglo-
bulin) and chemotherapeutic agents (such as etoposide)
required to decrease hyperinflammation (Henter et al, 1997,
2007; Jordan & Filipovich, 2008; Mahlaoui et al, 2007).
Removal of the infectious agent is often not sufficient, effective
or rapid enough to enable recovery from HLH. Immunosup-
pressive/chemotherapeutic treatment must be combined
with anti-infective therapy to induce remission from HLH.
There is thus an overall pressing need for effective, less toxic
immunosuppressive/chemotherapeutic treatments in HLH.
Several cytokines that promote HLH have been identified and
are therefore candidate targets for reducing hyperinflammation.
Of these various cytokines, IFNg appears to be a promising
candidate. Indeed, elevated serum IFNg levels have been found
in HLH patients (Henter et al, 1991; Mazodier et al, 2005;
Nagasawa et al, 2008; Osugi et al, 1997; Takada et al, 2003) and
IFNg production was detected in the liver (Billiau et al, 2005).
Elevated IFNg levels were also found in murine models of
HLH after triggering the condition by infection with lymphocytic
choriomeningitis virus (LCMV) (Crozat et al, 2007; Czar et al,
2001; Jordan et al, 2004; Pachlopnik Schmid et al, 2008). It
was furthermore shown that administration of anti-IFNg
antibodies to perforin-deficient mice during incubation of
the LCMV infection increased survival and prevented the
development of aplastic anaemia and other manifestations of
HLH (Badovinac et al, 2003; Binder et al, 1998; Jordan et al,
2004).
In the present study, we looked at whether administration
of an anti-IFNg antibody would have not only a preventive but
also a therapeutic effect in perforin-deficient (pfp/)
mice with HLH as a preclinical model. Furthermore, we
hypothesized that other genetic causes of HLH share a common
effector pathway and therefore extended our study to the
examination of Rab 27a-deficient (Rab27a/) mice with
HLH; a murine genetic model of human Griscelli syndrome
type 2.
RESULTS
Improved survival and recovery with anti-IFNg treatment
The effects of IFNg neutralization were tested in pfp/ and
Rab27a/ mice that display the features of LCMV-induced
HLH. After LCMV injection, pfp/ and Rab27a/mice were
visibly more ill than control mice, as evidenced by lethargy,
scrubby fur, loss of colour in the paw pads, unstable move-
ments, hunched back and turbid eyes appearing 7–10 days after
LCMV injection. In the absence of treatment or following the
administration of a control antibody, all pfp/ mice died
within 8 and 21 days after injection of 100 pfu of LCMV
respectively (Fig 1A). All wild-type (wt) mice survived (data not
shown). Next, 100 pfu of LCMV was injected into pfp/ mice
on day 0 and treatment with the anti-IFNg antibody XMG1.2was
initiated on day 8, when signs of HLH (such as changes in body
temperature, splenomegaly, pancytopenia, hypertriglyceridae-
mia and haemophagocytosis as discussed below) were first
detected. Anti-IFNg treatment (consisting of five injections,
given every 3rd day from day 8 until day 20) improved survival
of LCMV-infected pfp/mice with HLH, when compared with
the control group (p< 0.0001). Nine out of the 11 mice in the
anti-IFNg treatment group survived. The experiment was
concluded on day 27 post-LCMV injection in one group of
mice (n¼ 3). No additional deaths occurred in the remaining
mice (n¼ 6) observed until day 36. Anti-IFNg antibody-treated
pfp/ mice had a better general condition, increased spon-
taneous locomotion, defense reactions and controlled, flowing
movements when compared with the control group. One
mouse within the treatment group died immediately after the
first anti-IFNg antibody injection—HLH was probably
already too advanced. Another mouse within the treatment
group died on day 15 after LCMV injection and showed a
haemorrhagic abdominal cavity—probably as a consequence
of traumatic bleeding caused by the injection of anti-IFNg
antibody on day 14. Following LCMV injection, wt mice
stopped gaining body weight, while pfp/ mice lost body
weight. Weight loss was attenuated by anti-IFNg antibody
treatment in pfp/ mice (Fig 1B). The mice were febrile on
day 6 (Fig 1C). Wt mice had normal to slightly elevated body
temperatures thereafter, whereas pfp/ mice developed
hypothermia. Hypothermia was controlled by anti-IFNg treat-
ment (Fig 1C).
Although Rab27a/ mice were visibly ill after LCMV
injection, mortality was observed in only one out of five
untreated mice and zero out of five control antibody-treated
mice (Fig 1D). Survival in anti-IFNg-treated mice (n¼ 5) was
100%. Treatment consisted of four injections, given every 3rd
day from day 13 until day 22 after LCMV injection. The
experiment was concluded on day 25 post-LCMV injection in
one group of mice (n¼ 8, with four anti-IFNg-treated and four
control antibody-treated animals). No additional deaths occur-
red in the remainingmice (n¼ 6) observed until day 34. Another
group ofmice (n¼ 4, with two anti-IFNg-treated and two control
antibody-treated animals) was observed until day 70 and no
deaths occurred in this group. Given the survival of infected,
untreated Rab27a/ mice with HLH, we considered that this
mouse model was useful for studying differences between
treatment and control groups in more phenotypic detail. In
Rab27a/ mice, anti-IFNg treatment improved the general
clinical condition (data not shown) and attenuated weight
loss, when compared with control antibody treatment (Fig 1E).
Hypothermia in Rab27a/mice was reduced by anti-IFNg,
when compared with control antibody treatment (Fig 1F). The
clinical condition of untreated (data not shown) and control
antibody-treated Rab27a/mice improved spontaneously, so
that there was no significant difference in body weight
from day 40 and in body temperature from day 25 post-LCMV
injection onwards, when compared with anti-IFNg-treated
mice.
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Improved haematological parameters with anti-IFNg
treatment
A drop in the haemoglobin level, neutrophil and thrombocyte
counts is one of themajor features in humanHLH.We, therefore,
analysed these parameters in mice before and during anti-IFNg
treatment. Although anaemia and thrombocytopenia were found
in all animals (i.e. wt, pfp/, Rab27þ/ and Rab27a/
mice) on day 8 after LCMV injection, these parameters were
significantly lower in pfp/ and Rab27a/ mice than in the
controls (Fig 1G and data not shown). Absolute neutrophil
counts decreased slightly in pfp/ and Rab27a/ mice,
while an increase was observed in wt mice on day 8 after LCMV
injection. All parameters improved in pfp/mice on anti-IFNg
treatment and returned to normal levels two to three weeks after
therapy initiation, whereas control antibody-treated pfp/
mice succumbed at the nadir. Given that Rab27a/ mice with
HLH survived even in the absence of treatment, it was possible to
compare the respective blood counts for anti-IFNg- and control
antibody-treated mice for a longer period of time. Blood cell
counts increased during anti-IFNg treatment, while pancytope-
nia persisted in control antibody-treated mice (Fig 1H).
Histopathological features of bone marrow and spleen during
anti-IFNg treatment
The positive effect of anti-IFNg treatment on haematopoiesis was
also visible in bone marrow sections of pfp/ and Rab27a/
mice and through the presence of an increased red cell
distribution width, which is a parameter of active erythropoiesis
(Fig 2A and B and data not shown). Splenomegaly is one of the
diagnostic criteria for human HLH. We, therefore, analysed
spleen weight in mice during HLH and the subsequent anti-IFNg
treatment. However, spleen size may not be a fully accurate
parameter for murine HLH for several reasons. Firstly, in
contrast to human, mouse spleens continue to function as a
haematopoietic organ in postnatal life. This could have an impact
on the spleen size as a readout criterion in a disease like HLH,
where active haematopoiesis is a sign of recovery. Secondly,
spleen size in pfp/ mice did not correlate with disease
severity, since spleens in LCMV-infected pfp/mice with HLH
were not significantly enlarged when compared with LCMV-
infected wt mice (Fig S1A of Supporting Information). Thirdly,
spleen size in pfp/ mice tended to correlate with the LCMV
dose administered (Pearson r¼ 0.9) (Fig S1B of Supporting
Information). In Rab27a/ mice, spleen size was substantially
increased on day 13 post-LCMV injection, i.e. prior to any
antibody treatment (Fig S1C of Supporting Information). Spleen
size tended to decrease in anti-IFNg-treated Rab27a/ mice,
whereas there was no significant change in control antibody-
treated mice. The anatomical structure of the spleen was
markedly modified by HLH. The red pulp was enlarged and
the white pulp was disorganized (Fig 2C and D). Interestingly,
anti-IFNg antibody treatment almost completely normalized the
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Figure 1. Anti-IFNg treatment improves survival and clinical as well as
haematological recovery. In the panels on the left-hand side, data from pfp/
mice are shown that were injected with LCMV (100 pfu) on day 0 and treated
either with anti-IFNg or with control antibodies from day 8 to day 20 (five
injections); in the panels on the right-hand side, data from Rab27a/mice are
shown that were injected with LCMV (500 pfu) on day 0 and treated either with
anti-IFNg or with control antibody from day 13 to day 22 (four injections); open
squares indicate control mice (wt and Rab27aþ/), black trianglesmice treated
with anti-IFNg (pfp/ and Rab27a/) and grey dots mice treated with
control antibody (pfp/ and Rab27a/).
A–C. (A) Survival, (B) body weight and (C) body temperature of pfp/ mice.
D–F. (D) Survival, (E) body weight and (F) body temperature of Rab27a/
mice.
G. Blood haemoglobin level and thrombocyte and neutrophilic granulocyte
counts in pfp/ mice.
H. Blood haemoglobin level and thrombocyte and neutrophilic granulocyte
counts in Rab27a/mice. The dashed lines in (G) and (H) correspond to
normal values in C57BL/6J wt mice given in the book by Metcalf (2005).
Blood counts are representative for two independent experiments;
p< 0.05; p<0.005, p<0.001.
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anatomical structure in both, pfp/ and Rab27a/mice, with
restoration of the white pulp’s initial condition.
Attenuated development of cerebral infiltrates during anti-
IFNg treatment
Involvement of the central nervous system (CNS) is one of the
major concerns in humanHLH.We, therefore, analysed cerebral
histopathology in mice with HLH after anti-IFNg treatment.
Cerebral histopathological changes were not present in
Rab27a/ before anti-IFNg treatment on day 13 after LCMV
injection (data not shown). However, diffuse lymphocyte
infiltrations, intraparenchymal lymphocytic accumulation and
perivascular (pericapillar) cuffs were present in Rab27a/
mice at day 25 after control antibody treatment (Fig 2E) and
consisted of Granzyme B positive CD8 T-cells (data not shown).
In contrast, there were no intraparenchymal lymphocytic
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Figure 2. Histopathological features of bone marrow,
spleen and brain before and after anti-IFNg treatment.
A, B. Bone marrow sections of the right femur from
(A) wt and pfp/ mice and (B) Rab27aþ/
and Rab27a/ mice at different times after
LCMV-injection, without any antibody
treatment, after treatment with control or
with anti-IFNg antibody; treatment schedules
were the same as indicated for Fig 1; 25
objective lens.
C. Spleen sections from wt and pfp/ mice at
different times after LCMV-injection, without
any antibody treatment or after treatment
with anti-IFNg antibody (r¼ red pulp,
m¼marginal zone and w¼white pulp).
D. Spleen sections from a Rab27aþ/ and
Rab27a/ mice at different times after
LCMV-injection, without any antibody
treatment, after treatment with control or
with anti-IFNg antibody (r¼ red pulp,
m¼marginal zone and w¼white pulp); 10
objective lens.
E. Left panels: Brain sections showing
parenchyma with discrete lymphocytic
infiltrates in a Rab27aþ/ mouse;
Middle panels: a diffuse lymphocytic infiltrate
in the subcortical region (red arrowheads),
meningitis (arrow), a perivascular cuff (asterix)
and an intraparenchymal lymphocytic cluster
(white arrowhead) in a Rab27a/ mouse
after control antibody treatment;
Right panels: discrete lymphocytic infiltrates in
a Rab27a/ mouse after anti-IFNg
treatment, all analysed on day 25 after LCMV
injection; Upper panels: 25 objective lens,
lower panels: 100 objective lens.
Representative histological sections stained
with haematoxylin and eosin are shown.
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clusters and no signs of vasculitis in anti-IFNg treated mice.
Thus, cerebral histopathological changes that developed in
Rab27a/mice treated with control antibody were prevented
by anti-IFNg treatment.
Neutralization of IFNg
IFNg serum levels were increased in pfp/ and Rab27a/
mice on day 8, whereas wt and Rab27aþ/ mice showed only a
moderate peak on day 6 after LCMV infection (Fig 3A and B).
Some of the control antibody-treated pfp/ mice died at the
IFNg peak, while the others died once the IFNg serum level had
decreased. Surprisingly, a delayed decrease in IFNg serum levels
was observed in mice treated with anti-IFNg antibodies. This
effect could have resulted from the formation of immune
complexes between IFNg and the anti-IFNg antibody. Such
complexes were indeed detected in the serum of these animals
(Fig 3C). At later time points after antibody treatment, IFNg was
no longer detectable (data not shown). Immune complex
formation probably increased the half-life of IFNg and we,
therefore, analysed whether IFNg was biologically active.
Quantification of inducibly expressed GTPase (IGTP) transcrip-
tion in the macrophage cell line RAW264.7 is a reliable test to
measure the biological activity of IFNg since its transcript levels
strikingly correlatedwith IFNg concentrations as evidenced in Fig
S2 of Supporting Information. The serum-induced IGTP transcript
level was considerably reduced, reaching control value, on using
serum of anti-IFNg treated mice compared to serum of untreated
mice (Fig 3D and E). Thus, anti-IFNg treatment was effective in
inhibiting the biological activity of IFNg.
Cytokine levels in anti-IFNg-treated pfpS/S and
Rab27aS/S LCMV-infected mice
In order to establish whether or not the biological activity of
IFNg had been neutralized in vivo, we measured serum levels of
tumour necrosis factor (TNF)-a, granulocyte monocyte colony
stimulating factor (GM-CSF) and interleukin (IL)-12p70 in
pfp/ and Rab27a/mice during anti-IFNg treatment (Fig 3F
and G). Serum levels of TNF-a were found to be lower in anti-
IFNg treated compared to control antibody treated mice in both
murine models. GM-CSF levels were also lower in anti-IFNg
treated compared to control antibody treated mice, however a
significant difference was solely observed in Rab27a/ mice.
Similarly, IL-12p70 levels decreased upon anti-IFNg treatment.
The high mortality of control antibody treated pfp/ mice
impaired cytokine measurements at late time points. However,
during anti-IFNg treatment, there was no significant difference
in the serum levels of chemokine ligand 5 (CCL5), a chemokine
mostly secreted by activated T-cells. IL-17 levels showed a
tendency to increase in anti-IFNg-treated pfp/ and
Rab27a/mice when compared with control antibody treated
mice. However, the difference in IL-17 levels between control
antibody- and anti-IFNg-treated mice was not significant, the
levels varied strongly from mouse to mouse and did not exceed
the levels found in LCMV-infected Rab27aþ/ control mice that
did not receive any antibody treatment. Furthermore, this slight
increase in IL-17 was transient and the mice did not show any
sign of autoimmunity during this time (data not shown).
Reduced macrophage activation in the liver during
anti-IFNg treatment
Given thatmacrophage activation is one of the hallmarks of HLH,
we analysed themorphology ofmacrophages in tissue sections of
LCMV-infected Rab27a/ mice. Macrophages were activated
(as assessed by increase in size and engulfment of other blood
cells, i.e. haemophagocytosis) in liver sections of pfp/ and
Rab27a/ mice before antibody-treatment and in Rab27a/
mice during control antibody treatment, when compared with
control (wt and Rab27aþ/) mice (Fig 4A and B). Liver sections
in control mice contained Kupffer cells, the liver’s resident
macrophages. Anti-IFNg treatment reduced macrophage activa-
tion, as evidenced by fewer activated macrophages with haemo-
phagocytosis in histological sections in both, LCMV-infected
pfp/ and Rab27a/mice, compared with mice prior to any
antibody treatment and those treated with control antibody
(Fig 4A and B and Table 1). Triglyceride and ferritin levels,
further parameters of HLH, were also found to be increased in
pfp/ and Rab27a/ mice before antibody treatment when
compared to control mice (Fig 4C–F). A significant reduction in
triglyceride and ferritin levels was observed over time.
Persistence of virus in anti-IFNg-treated mice
Because of the genetic defect in cytotoxicity, LCMV persisted in
both pfp/ and Rab27a/ mice. Given that IFNg neutraliza-
tion is immunosuppressive, we compared the viral load in anti-
IFNg and control antibody-treated mice to assess the effect on
virus replication control. There was no consistent association of
the viral load with anti-IFNg treatment since there was neither a
difference in viral load between anti-IFNg and control antibody
treated Rab27a/mice nor an increase in viral load in anti-IFNg
treated mice when compared with mice before treatment in both
murine models, pfp/ and Rab27a/ mice (Fig 5A and B).
Viral persistence in the liver was also visualized by immunohis-
tochemical analyses. Viral antigen was detected in periportal
infiltrates in the vicinity of CD3 and Granzyme B positive cells.
Similar infiltrates were observed in all three groups, anti-IFNg
treated pfp/ mice, anti-IFNg and control antibody-treated
Rab27a/ mice (Fig 5C, Fig S3 of Supporting Information and
data not shown). Despite persistence of virus and periportal
infiltrates, serum aspartate-aminotransferase levels (a measure of
liver pathology) did not increase over time (Fig 5D and E). Taken
as a whole, our results show that anti-IFNg therapy reduced the
consequences of macrophage activation but did not have any
consistent influence on the LCMV load, at least during the course
of treatment used in this study.
DISCUSSION
We treated perforin-deficient mice and Rab27a-deficient mice
suffering from LCMV-induced HLH with either anti-IFNg or
control antibodies. Our study demonstrated that anti-IFNg
antibody treatment had a marked therapeutic effect on HLH in
both models. LCMV-infected perforin- and Rab27a-deficient
mice developed pancytopenia, splenomegaly, body temperature
changes, hypercytokinaemia and histopathological features
Research Article
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Figure 3. Neutralization of IFNg and decrease of macrophage derived cytokine levels with anti-IFNg treatment.
A, B. IFNg serum levels in (A) pfp/ and (B) Rab27a/ mice at various times after LCMV injection, as determined by ELISA. LCMV injections and antibody
treatments in all experiments were performed as indicated in Fig 1. Open squares indicate serum levels in wt (or Rab27aþ/) mice; grey dots, pfp/ (or
Rab27a/) mice treated with control antibody; black triangles, pfp/ (or Rab27a/) mice treated with anti-IFNg antibody. Values represent
mean standard error of the mean (SEM) (n 3 per group) and are representative for two independent experiments.
C. Serum levels of immune complexes of rat IgG andmouse IFNg in pfp/mice. Serum levels of immune complexes weremeasured on days 0, 11 and 14 by ELISA
with goat anti-rat IgG as capture antibody and goat anti-mouse IFNg as revealing antibody. Dilution buffer was used as a negative control and rat anti-mouse
IFNg that was pre-incubated with mouse IFNg was used as a positive control. Values represent meanþSD of duplicate measurements (n¼ 3 per group).
D. IFNg serum levels of pfp/ mice on day 8 (i.e. before anti-IFNg) and day 14 (i.e. during anti-IFNg treatment) as determined by ELISA.
E. Serum-induced IGTP transcript levels in RAW264.7 cells by the same serum samples as in (D), measured by quantitative RT-PCR. The data show the fold
difference in the IGTP-transcript compared to stimulation with cell culture medium alone. Values represent mean SEM (n¼ 5 per group from two
independent experiments).
F, G. Serum levels of TNF-a, GM-CSF, IL-12p70, CCL5 and IL-17 in (F) pfp/ mice on day 12 (or day 36) and in (G) Rab27a/ mice on day 18 after LCMV-injection
treated with control or anti-IFNg antibody, measured by Multiplex cytokine assay. Values represent meanþSD (n 3 per group) and are representative of two
independent experiments. White bars indicate measurements in wt (or Rab27aþ/) mice, grey bars pfp/ (or Rab27a/) mice treated with control
antibody and black bars pfp/ (or Rab27a/) mice treated with anti-IFNg antibody. p<0.05, p<0.005, p<0.001.
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Figure 4. Reduced macrophage activation after
anti-IFNg treatment.
A, B. Liver sections stained with anti-macrophage
antibody F4/80 in (A) wt and pfp/mice and
in (B) Rab27aþ/ and Rab27a/ mice at
different times after LCMV-injection, without
any antibody treatment, after treatment with
control or with anti-IFNg antibody; treatment
schedules were the same as indicated for Fig 1;
arrows indicate the corresponding cells at
different magnifications; arrowheads indicate:
H¼ nucleus of hepatocyte, M¼ nucleus of
macrophage, p¼ phagocytosed cell, Mþ P
indicating haemophagocytosis; 25 and 100
objective lens as indicated.
C, E. Serum triglyceride levels in (C) pfp/ and
(E) Rab 27a/ mice.
D, F. Serum ferritin levels in (D) pfp/ and (F) Rab
27a/ mice. Meanþ SD of measurements
(n 4 per group). #p>0.05, p<0.05,
p<0.001.
Table 1. Quantification of haemophagocytosis in liver sections
Number of macrophages with haemophagocytosis
pfp/ Rab27a/
Day after LCMV injection 8 27 p 18–25 18–25 p
Antibody treatment No Anti-IFNg Control Ab Anti-IFNg
Mean SEM1 249.9 23.6 44.8 5.3 <0.0001 102.98.4 63.7 7.2 0.0010
Quantification of macrophages with engulfed blood cells. Histological analysis of liver sections was performed on ten visual fields (10 objective lens) per mouse
with two mice per group, with each visual field subdivided into 20 quadrants. The number of macrophages with haemophagocytosis was counted in at least 100
representative quadrants per mouse. The number of macrophages with haemophagocytosis is expressed as the count per 100 quadrants.
1mean number of macrophages with engulfed cells per 100 quadrants standard error of the mean (SEM).
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characteristic of HLH (such as bone marrow hypoplasia,
disturbance in splenic architecture and haemophagocytosis).
This is consistent with previous studies of perforin- and Rab27a-
deficient mice (Binder et al, 1998; Jordan et al, 2004; Pachlopnik
Schmid et al, 2008) and confirms that these mice represent
reliable models of human HLH. A prime role of IFNg in the
pathogenesis of haemophagocytosis has been shown; secondary
prevention by anti-IFNg antibodies increased the survival rate
and had a preventive effect on the development of aplastic
anaemia and other signs of HLH in perforin-deficient mice
(Badovinac et al, 2003; Binder et al, 1998; Jordan et al, 2004).
Herein, we show that delayed administration of an IFNg-
neutralizing antibody led to recovery from HLH in perforin- and
Rab27a-deficient mice, based on prevention of death in perforin-
deficient mice and the correction of pancytopenia, moderation
of weight loss and hypothermia, reduction of macrophage-
dependent cytokinaemia, restoration of splenic architecture and
reduction of haemophagocytosis in the liver of both murine
models. Thus, we achieved a therapeutic, not only a preventive,
effect. CNS affection is a major concern in HLH and has a
significant impact on the long-term outcome of the patients. The
effect of IFNg neutralization on CNS involvement has not been
investigated so far in HLH. We show that in HLH anti-IFNg
therapy has a beneficial effect on CNS lymphocytic infiltration.
HLH was less fatal in the Rab27a-deficient mice than in the
perforin-deficient animals, since most of the former survived
HLH in the absence of IFNg neutralization. This is reminiscent of
the respective human conditions, since disease onset occurs
later in patients with nonsense mutations in Rab27a (Griscelli
syndrome type 2) than in those with nonsense mutations in
perforin (familial HLH type 2) (Feldmann et al, 2002; Horne et
al, 2008; Mamishi et al, 2008). Furthermore, NK cells derived
from patients with Griscelli syndrome type 2 exhibit residual
cytotoxicity (Gazit et al, 2007; Plebani et al, 2000).
Our results demonstrate that the pathophysiology of HLH can
be divided into two steps: (i) virus-triggered CD8 T-cell
activation/expansion that results in high, sustained production
of IFNg in the absence of virus clearance and (ii) IFNg-mediated
macrophage activation. Only the second step is inhibited by the
anti-IFNg antibody. It is worth emphasizing that this is enough
to enable survival of LCMV-infected, perforin-deficient mice
with HLH and to alleviate most of the HLH symptoms in
perforin- and Rab27a-deficient mice. These results highlight the
central role of IFNg-driven macrophage activation in HLH,
defining this condition as a unique pathophysiological entity.
Apparently, there is a significant prevention of T-lymphocytic
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Figure 5. Persistence of virus and lymphocytes in
the liver of anti-IFNg-treated mice.
A, B. Viral load in livers and spleens of (A) pfp/
and (B) Rab27a/ mice as measured by
quantitative PCR, expressed as number of
LCMV-copies per mill b-actin-copies.
Measurements in (A) were performed on day 0,
8 and 27, in (B) on day 0, 13 and 25 after LCMV-
injection. Striped bars indicate measurements
in LCMV-infected mice before any antibody
treatment, black bars mice treated with anti-
IFNg antibody and grey bars Rab27a/mice
treated with control antibody. Values
represent meanþ SD from two independent
experiments.
C. Infiltration in the portal tract of liver sections
stained with antibodies to LCMV (left panel),
CD3 (middle panel) and Granzyme B (right
panel) from a pfp/ mouse that was treated
with anti-IFNg antibody from day 8 to day 20
and analysed on day 27 after LCMV injection;
25 objective lens. Images are also
representative for immunohistochemical
stainings in Rab27a/ under anti-IFNg as
well as under control antibody treatment.
D, E. Aspartate aminotransferase (ASAT) levels in
the serum of (D) pfp/ and (E) Rab27a/
mice before and after LCMV-injection,
receiving anti-IFNg or control antibody
treatment. Values represent meanþ SD (n¼ 4
per group); LCMV injections and antibody
treatments in all experiments were performed
as indicated in Fig 1. #p>0.05, p<0.05,
p< 0.001.
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infiltrates in the brain during anti-IFNg therapy. This contrasts
with a persistence of hepatic T-cell infiltrates in the treated
animals. This difference might be explained by the hepatotropic
nature of the LCMV strain in this study. Another explanation
could be an anti-inflammatory effect of the anti-IFNg therapy,
which by reducing the production of macrophage-derived
cytokines might help to normalize the blood–brain barrier
tightness (Abbott et al, 2006; Polavarapu et al, 2005).
Delayed clearance of IFNg in perforin- and Rab27a-deficient
mice receiving anti-IFNg treatment may be explained by the
formation of immune complexes between IFNg and anti-IFNg
antibodies. Previous studies have shown that other antibodies
used as therapeutic agents may also increase the half-life of their
antigen, even though these antibodies neutralize the biological
activity of the latter (Corne et al, 1997; Lainee et al, 2005; Rojas
et al, 2005). Such immune complexes do not appear to be
detrimental to the hosts.
Perforin-deficient mice not treated with anti-IFNg succumbed
soon after disease onset. Thus, the treatment had to be initiated
early on in the time-course of the active disease. In contrast, most
Rab27a-deficient mice survived LCMV-induced HLH—even in
the absence of IFNg neutralization. Therefore, the Rab27a-
deficient mouse model provided us with an opportunity to study
the effect of anti-IFNg antibody at a later stage in HLH and com-
pare it with a control antibody treatment group. In addition, the
Rab27a-deficient model makes it possible to clearly distinguish
HLH-associated phenomena from perimortem events. Even
though anti-IFNg treatment was started late (day 13) in disease
progression, a remarkable therapeutic effect was equally
observed in Rab27a-deficient mice when compared with
perforin-deficient mice treated early in the course of the disease.
This study shows that anti-IFNg treatment induces recovery
from HLH, despite viral persistence. Although the general
condition of perforin- and Rab27a-deficient mice with HLH
clearly improved during treatment with anti-IFNg antibodies, the
treated mice were not completely healthy and did not regain full
body weight, compared with non-infected littermates. The
treated mice showed persistent periportal T-cell infiltrates in
the liver. The location of these infiltrates was very similar to that
observed in LCMV-infected IFNg/mice and in other types of
chronic viral hepatitis (Kunar et al, 2005; Moskophidis et al,
1994; Nansen et al, 1999). We show that these T-cell infiltrates
were associated locally with areas of LCMV detection —strongly
suggesting the presence of active, LCMV-driven T-cell responses.
Thus, the incomplete recovery of the mice with LCMV-triggered
HLH that had been treated with anti-IFNg antibodies can
probably be explained by viral persistence. It is likely that
insufficient cytotoxicity (due to the perforin- or Rab27a-
deficiency) impaired the killing of infected cells and thereby
enabled viral persistence. Although neutralization of IFNg per se
might have compromised virus control (Moskophidis et al, 1994;
Nansen et al, 1999), it had no detectable effect on the viral load.
In view of the efficacy shown in the present study, we suggest
that IFNg neutralization could be useful for reducing the signs of
HLH in patients. This conclusion is supported by the striking
similarity between HLH occurring in humans and in relevant
animal models, as shown here and in Unc13-d (the mouse
orthologue of human Munc13-4)-deficient mice (Crozat et al,
2007) by the substantially elevated serum IFNg levels in murine
HLH. Patients with inherited and acquired HLH have very high
IFNg serum levels during the active disease (Henter et al, 1991;
Mazodier et al, 2005; Nagasawa et al, 2008; Osugi et al, 1997;
Takada et al, 2003 and our own unpublished observations). An
anti-human IFNg antibody (fontolizumab) has been shown to
be safe in clinical trials in Crohn’s disease (Hommes et al, 2006;
Reinisch et al, 2006). In addition, fontolizumab’s therapeutic
effects have been documented in patients with inflammatory
skin diseases and in a clinical trial of patients with corneal
transplant rejection (Skurkovich et al, 2002; Skurkovich &
Skurkovich, 2005). The patient numbers might not be large
enough to draw any firm conclusions on any infectious,
neoplastic and allergic complications potentially attributable
to fontolizumab. However, the effect of neutralizing IFNg on the
response to infection is probably minor for a short period of
therapy. Indeed, patients with inborn errors of the IL-12/23-
IFNg loop display normal resistance to most infections, with the
notable exception of mycobacteria and, in some cases,
Salmonella (Mansouri et al, 2005). However, such infections
require a persistent defect in the IL-12/23-IFNg loop. It is also
noteworthy that delayed neutralization of IFNg improved
survival rates and attenuated organ dysfunctions in a primate
model of bacteriaemic shock (Lainee et al, 2005).
Alternatively, this treatment could be especially attractive in
patients with hereditary HLH, given that current drugs such as
etoposide (Henter et al, 2007) or antithymoglobulin (Mahlaoui et
al, 2007) can be toxic and are farmore immunosuppressive than a
transient IFNg blockade. Another potential advantage of an IFNg
blockade in the management of inherited HLHmight be its ability
to improve engraftment in haematopoietic stem cell transplanta-
tion (Rottman et al, 2008), the curative step in the therapy of
inherited HLH. Neutralization of IFNg might also be an efficient
and safe way to treat patients with acquired HLH (acquired HLH
has been observed notably in severe infections, malignancies,
autoimmune, autoinflammatory and rheumatic diseases)
(Emmenegger et al, 2005; Hsieh & Chang, 2006), provided that
the T-cell activation trigger is also amenable to therapy.
In conclusion, the present study shows that treatment of HLH
with IFNg-blocking antibodies induces recovery and improves
survival rates in two different murine models, despite the
persistence of the initial infectious trigger. In view of the fact that
humanized anti-IFNg antibodies are reportedly safe in clinical
trials of other diseases, further investigation is warranted in
order to determine their potential clinical efficacy in hereditary
and acquired forms of HLH.
MATERIALS AND METHODS
Mice
C57BL/6J wt, C57BL/6J-Prf1tm1Sdz/J (herein after referred to as pfp/)
and C3H/HeSn-Rab27aash/J (so-called ashen mice) were purchased
from the Jackson Laboratory. C57BL/6J-Rab27a ash/j (Rab27a/) mice
were obtained by backcrossing C3H/HeSn-Rab27aash/J with C57BL/6J
wt mice for 10 generations. For experiments with Rab27a/ mice,
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the offspring of a heterozygous X homozygous crossing were used.
Heterozygous offspring were used as controls in the experiments with
Rab27a/ mice. Mice were maintained and handled in accordance
with the national and institutional polices. The study protocol was
approved by the local ethics committee. Body temperature was
measured using a rodent rectal thermometer (BIOSEB).
The presence of the Rab27a-mutation was verified by restriction site
analysis of polymerase chain reaction (PCR) products of mouse tail DNA.
Briefly, 0.5 cm from the end of a mouse’s tail was incubated at 378C in
lysis buffer (50mMTris-Cl pH 8.0, 100mMEDTA, 100mMNaCl, 1% SDS)
containing proteinase K (0.7 mg/ml) overnight. DNA was extracted
thereafter using phenol/chloroform. PCR was performed using the
following primers: forward: 50-CTTTCTCTTCCACCATACTT-30 and reverse:
50-AAGCGAGTTCCAGGGCAG-30 . The PCR products were purified using a
PCR Purification Kit (QIAGEN), restricted by RsaI at 378C for 4 h and then
separated on a 2% agarose gel containing ethidium bromide. DNA from
Rab27a/ mice produced a single, 534 bp band, DNA from wt mice
produced a 242 bp band and a 291 bp band and DNA from heterozygous
mice resulted in three bands with 534, 291 and 242 bp, respectively.
Viral preparations
LCMV WE (Battegay et al, 1991), kindly provided by Professor Maries
van den Broek and Professor Rolf Zinkernagel (University of Zu¨rich,
Switzerland), was injected intraperitoneally to 6–8 weeks old pfp/
and 6–14 weeks old Rab27a/mice. Infected animals and biological
material potentially containing LCMV were handled in a Biosafety Level
2 environment.
Treatment schedules
In pfp/mice and their wt controls, 100 pfu of LCMVwere injected on
day 0 and treatment with anti-IFNg antibodies was initiated on day 8.
This viral dose was chosen because it induced mortality in 100% of
pfp/ mice, while the treatment time was chosen because the mice
then showed multiple features of HLH (thus enabling assessment of a
potential therapeutic effect of the anti-IFNg antibody injections). It should
be noted that some of the mice already succumbed at this time. There
were no significant differences between infected, untreated (n¼7) and
infected, control antibody-treated (n¼4) pfp/mice in terms of any of
the tested parameters and so the two groups were pooled. Rab27a/
mice and their heterozygous controls received a dose of 500 pfu of LCMV
on day 0. This dose was chosen because it resulted in the highest serum
IFNg-levels, compared with mice that had received a higher (1104 pfu)
or a lower (100 pfu) viral dose (data not shown).The treat-mentwith anti-
IFNg antibodies in Rab27a/ mice was started later than in pfp/
mice (namely on day 13 after LCMV injection) because we sought to
initiate treatment as late as possible during the active phase of HLH, in
order to better assess the effect of anti-IFNg therapy. The data shown are
representative of 2–7 independent experiments.
Blood counts and ferritin
Blood counts were determined using the MS 9-5V automated cell
counter (Melet Schloesing Laboratories). For ethical reasons, con-
secutive blood samples from the same animals were taken from the tail
vein instead of the orbital cavity. This has to be taken into accountwhen
comparing blood counts presented here with those from other studies.
Ferritin levels were determined using an enzyme-linked immunosor-
bent assay (ELISA) kit (ALPCO Diagnostics).
Cytokine measurements and antibodies
IFNg levels in mouse sera were determined using ELISA kits (R&D
Systems), the other cytokine serum levels by a BioPlex custom-mixed
immunoassay panel run on a BioPlex 200 System and analysed using
BioPlex Manager software (version 4.1, BioRad Laboratories). Immune
complexes were detected by ELISA using goat anti-rat IgG (Kirkegaard &
Perry Laboratories), recombinant mouse IFNg, biotinylated goat anti-
mouse IFNg and streptavidin-horseradish peroxidase (all from R&D
Systems). Optical density (OD) was measured at 450 nmwith a 570 nm
reference filter.
For treatment experiments, XMG1.2 and Y13-259 antibodies were
used. Intraperitoneal antibody treatment was performed with 0.5 mg
antibody/mouse every 3rd day. A hybridoma producing XMG1.2 (a rat
IgG1monoclonal antibody directed against mouse IFNg) (Cherwinski et
al, 1987) was used for antibody production in mouse ascites.
Affinity chromatography purification on protein G Sepharose was
performed by BIOTEM (Le Rivier d’Apprieu, France).The control antibody
Y13-259 (ATCC CRL-1742, a rat IgG1 antibody directed against RAS
p21) was produced using a recombinant mammalian expression
system.
Immunohistochemistry was performed using cell and tissue staining
kits (R&D Systems) with monoclonal rat IgG2b anti-mouse macrophage
antigen F4/80, monoclonal rat IgG1 anti-human CD3 crossreacting with
mouse CD3 (clone CD3-12), rat IgG1 negative control (all from Serotec
AbD), rat IgG2b negative control (Pharmingen), GRB7 (a monoclonal
rabbit anti-granzyme B7) (Santa Cruz), rabbit serum (as a negative
control) and biotinylated mouse IgG1 (as a negative control). The
hybridoma producing KL-25 (a monoclonal mouse IgG1 anti-LCMV WE
GP-1) was kindly provided by Professor Michael Buchmeier (Scripps
Research Institute, USA) in agreement with Professor Demetrius
Moskophidis (Medical College of Georgia, USA) (Bruns et al, 1983).
KL-25 antibody (produced and purified by BIOTEM) was biotinylated
using Biotin-X-NHS (Calbiochem). Immunohistochemistry was performed
on cryosections with the exception of F4/80 and its negative control,
which were used on paraffin-embedded sections, pretreated with
Proteinase K (20 mg/ml, 3 min). Counterstaining was performed with
haematoxylin. Images from immunohistochemistry experiments with
negative control antibodies are not shown.
Organ weight and pathology
Organs were removed from sacrificed mice that had been infused with
20 ml of 48C phosphate buffered saline (PBS) containing 2 mM EDTA.
Total body weight was measured before infusion, while organ weight
wasmeasured after infusion and removal.Tissues were fixed in formalin
4% for 24 h, embedded in paraffin and stained with haematoxylin and
eosin. Alternatively, tissues were fixed in 4% paraformaldehyde,
cryoprotected by sucrose 30%, embedded in Cryomolds (Siemens
Medical Solutions DIAG SAS) and snap frozen in liquid nitrogen. Light
microscopy was performed using Axioplan 2 microscope (Zeiss), a
QICAM Fast 1394 camera and Qcapture software (Qimaging).
Cells and cell culture
RAW264.7 cells (ATCC TIB-71) were cultured in RPMI 1640 medium
with 2.05 mM L-glutamine (GIBCO) supplemented with 5% (v/v)
heat-inactivated fetal bovine serum. Mouse sera were added directly to
the culture medium (using the same dilution for all sera) and thereafter
incubated with RAW264.7 cells at 378C, 5% CO2 for 4 h.
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Quantitative PCR
RNA was isolated from tissue samples and RAW264.7 cell cultures
using the RNeasy Mini Kit (Qiagen), depleted in genomic DNA and then
reverse transcribed into c-DNA using Quantitect (Qiagen).
LCMV: cDNA-preparations from five mouse livers (12–27 days after
LCMV infection) were sequenced for LCMV to make sure that there were
no mutations in the LCMV WE NP that would interfere with
quantitative PCR analysis. In order to estimate the LCMV copy number,
PCR products from b-actin and LCMV NP were cloned into pCR2.1-
TOPO using XhoI forward primer: 50-CTCGAGAAGGTGTGAT-30 , NotI‘
reverse primer: 50-TGCTTCTAGGCGGACTGCGGCC-30 and SacI forward
primer: 50-GAGCTCGAGTCCTTCACATCCCAAAC-30 and SpeI reverse pri-
mer: 50-ACTAGTATCAAGGACGCAACCAGT-30 , respectively, and according
to standard protocols (New England Biolabs). Quantitative PCR was
performed on cDNA isolated from tissue samples and on the pCR2.1-
TOPO plasmid containing b-actin and LCMV inserts using SYBR Green
PCR Master mix (Applied Biosystems) and the following primers: LCMV:
forward: 50-TCTCATCCCAACCATTTGCA-30 and reverse: 50-GGGAAATTT-
GACAGCACAACAA-30; b-actin: forward: 50-CCAGCAGATGTGGATCAGCA-30
and reverse: 50-CTTGCGGTGCACGATGG-30 .
IGTP: Quantitative PCR was performed on cDNA isolated from
RAW264.7 cell culture samples using TaqMan Universal PCR Master
mix (Applied Biosystems), a pre-designed gene expression assay for
mouse IGTP and the following b-actin-probe: FAM-50-CAGGAGTAC-
GATGAGTCCGGCCCC-30–TAMRA with the following primers for b-actin:
forward: 50-CCAGCAGATGTGGATCAGCA-30 and reverse: 50-
CTTGCGGTGCACGATGG-30 .
Fluorescence measurement during PCR (and subsequent dissocia-
tion, if using SYBR Green) was performed on an ABI 7900 cycler and
analysed using Sequence Detection Systems software (version 2.2.2,
Applied Biosystems).
Statistical analysis
Analyses were performed with Prism version 4 for Macintosh
(Graphpad). Survival curves were compared using the Logrank test.
All other statistical hypotheses were analysed using t-tests.
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The paper explained
PROBLEM:
Haemophagocytic lymphohistiocytosis (HLH) is a potentially fatal
inflammatory disease. It is characterized by fever, an enlarged
spleen, cytopenia, elevated blood ferritin, coagulopathy, blood lipid
changes and may also lead to neurological involvement. These
symptoms are the result of hypercytokinaemia and organ
infiltration by lymphocytes and macrophages. Current immuno-
suppressive and chemotherapeutic treatments needed to decrease
inflammation can have serious side effects and there is a pressing
need for effective, less toxic treatments in this disease.
RESULTS:
This manuscript shows that in vivo IFNg neutralization has a
dramatic curative effect on clinical and biological manifestations
of experimental HLH. Therapeutic administration of an anti-IFNg
antibody to two different murine models of human hereditary
HLH (perforin-deficient and Rab27a-deficient mice, both induced
by lymphocytic choriomeningitis virus) ameliorated many of the
HLH-related symptoms described above and induced recovery
from the disease.
IMPACT:
This study proves the therapeutic efficacy of anti-IFNg antibodies
in experimental HLH and could be considered as a preclinical
approach of an alternative HLH treatment.
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